Morgan Stanley analyst Kallum Titchmarsh assumed coverage of Adaptive Biotechnologies (ADPT) with an Equal Weight rating and a price target of $21, up from $16. Life Science Tools and Diagnostics end market bright spots are beginning to emerge and the firm sees “plenty of catalysts” in the pipeline across its coverage, adding that it sees “lots to like in the space entering 2026.” However, a recent industry valuation spike in the second half of the year leaves multiples in “a fair place,” so the firm starts the group with an In-Line industry view, the analyst tells investors. Among the group, the analyst identifies Danaher (DHR) as Top Pick.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies announces 90 abstracts to be presented at ASH meeting
- Adaptive Biotechnologies rises 11.3%
- Adaptive Biotechnologies price target raised to $16 from $11 at Morgan Stanley
- Adaptive Biotechnologies’ Earnings Call Highlights Growth and Challenges
- Adaptive Biotechnologies price target raised to $20 from $17 at JPMorgan